ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 533

NT-Probnp and Inflammation in Active Ankylosing Spondylitis Receiving TNF Blockers: Is There a Link?

Julio C. B. Moraes1, Ana C. M. Ribeiro2, Carla G.S. Saad3, Alessandro C. Lianza4, Nadia E. Aikawa5, Clovis Artur Silva6 and Eloisa Bonfa7, 1Reumatologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 3Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil, 4Radiology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 5Rheumatology, University of São Paulo, Sao Paulo, Brazil, 6Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, 7Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), anti-TNF therapy and inflammation, NT-proBNP

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose: Cardiovascular disease plays a central role in morbidity and mortality in rheumatic patients. N-terminal pro-brain natriuretic peptide (NT-proBNP) is a strong marker of cardiovascular risk with recent evidence that inflammation may also influence its levels. The discrimination of this confounding variable is of particular interest in rheumatic diseases. Therefore, we evaluated NT-proBNP in ankylosing spondylitis (AS) patients pre- and post-TNF blockage therapy to determine the possible association between NT-proBNP levels and inflammatory parameters.

Methods: Forty-five consecutive AS patients without previous/current cardiovascular disease or systolic myocardial dysfunction, who were eligible to anti-TNF therapy, were prospectively enrolled. All patients received TNF blockers (infliximab, adalimumab and etanercept in their regular schedule) and they were evaluated for circulating NT-proBNP levels, clinical and laboratory parameters of disease activity including BASDAI, ASDAS, ESR and CRP, traditional cardiovascular risk factors including blood pressure, body mass index, waist circumference and dyslipidemia; conventional and tissue Doppler imaging echocardiography and treatment data at baseline (BL) and six months after (6M). Statistical analysis included: Spearman rank order correlation, Mann-Whitney test or t-test to observe differences between patients with high or normal NT-proBNP levels at BL; paired-sample t tests or the Wilcoxon signed-rank test to observe differences between measurements at BL and 6M; Fisher exact test to compare categorical variables and multivariable linear regression analysis. All analyses used a two-sided significance level of 0.05.

Results: At BL, all patients had active AS, NT-proBNP levels had a median of 36 (20-72)pg/ml and 11% were high in spite of no systolic alteration. Multiple linear regression analysis revealed that this peptide, at BL, was independently correlated with ESR (p<0.001), age (p=0.01) and pulse pressure (p=0.01). After 6M, all disease parameters improved and NT-proBNP levels were significantly reduced [24 (16-47) pg/mL, p=0.037] compared to BL. Changes in NT-proBNP were positively correlated with ESR changes (r=0.41, p=0.006). Cardiovascular risk factors remained stable during follow-up.

Conclusion: Elevations of NT-proBNP should be interpreted with caution in active AS patients with no evidence of cardiovascular disease. The short-term reduction of NT-proBNP levels in these patients treated with anti-TNF therapy appears to reflect an improvement in inflammatory status. (ClinicalTrials.govnumber:NCT01072058).


Disclosure:

J. C. B. Moraes,
None;

A. C. M. Ribeiro,
None;

C. G. S. Saad,

Grants,

2;

A. C. Lianza,
None;

N. E. Aikawa,
None;

C. A. Silva,

Grants,

2;

E. Bonfa,

Grants,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nt-probnp-and-inflammation-in-active-ankylosing-spondylitis-receiving-tnf-blockers-is-there-a-link/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology